Norgine Pharmaceuticals
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Moorhall Rd, Harefield, Greater London, ...Phone Number
+44 1895826600Revenue
$46.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Norgine Pharmaceuticals
Adverse events should be reported. Both health professionals and patients can submit information through the Yellow Card website in the UK or the HPRA website in Ireland. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606. The scheme is used to collect information from health professionals and patients on suspected adverse drug reactions (ADRs). The continued success of the Yellow Card Scheme depends on your willingness to report suspected adverse drug reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie ; Email: medsafety@hpra.ie .Explore more
Popular SearchesNorgine Pharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Norgine Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Norgine Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Norgine Pharmaceuticals recently announced quarterly report
Check out if Norgine Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Norgine Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Norgine Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Norgine Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Norgine Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Norgine Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Norgine Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Norgine Pharmaceuticals
Compare insights from companies similar to Norgine Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Norgine Pharmaceuticals
$46.2M
51-200
Private
-
-
N/A
Company Profile Activity
Activity Insights
Norgine Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Norgine Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Norgine Pharmaceuticals.
Norgine Pharmaceuticals Tech Stack
A closer look at the technologies used by Norgine Pharmaceuticals
See more technologies
Norgine Pharmaceuticals News & Media
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with Localized, Non-Metastatic Solid Tumors ~Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Norgine Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Adverse events should be reported. Both health professionals and patients can submit information through the Yellow Card website in the UK or the HPRA website in Ireland. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606. The scheme is used to collect information from health professionals a... Read More
